Post Hoc Subgroup Analysis of ZEUS: Outcome On Renal Function, Efficacy and Safety in Living-Donor Kidney Transplant Recipients After Conversion From a Calcineurin Inhibitor to an Everolimus Based Regimen

被引:1
作者
Lehner, F. [1 ]
Sommerer, C. [1 ]
Arns, W. [1 ]
Reinke, P. [1 ]
Eisenberger, U. [1 ]
Wuthrich, R. [1 ]
Pressmar, K. [1 ]
Hauser, I. [1 ]
Porstner, M. [2 ]
May, C. [2 ]
Paulus, E. [2 ]
Muehlfeld, A. [1 ]
Suwelack, B. [1 ]
Wolters, H. [1 ]
Witzke, O. [1 ]
Stahl, R. [1 ]
Budde, K. [1 ]
机构
[1] ZEUS Study Grp, Nurnberg, Germany
[2] Novartis Pharmaceut, Nueremberg, Germany
关键词
D O I
10.1097/00007890-201407151-02074
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
C1917
引用
收藏
页码:613 / 613
页数:1
相关论文
empty
未找到相关数据